These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26606012)

  • 21. Hepatotoxicity induced by coxibs: how concerned should we be?
    Bessone F; Hernandez N; Roma MG; Ridruejo E; Mendizabal M; Medina-Cáliz I; Robles-Díaz M; Lucena MI; Andrade RJ
    Expert Opin Drug Saf; 2016 Nov; 15(11):1463-1475. PubMed ID: 27537326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the reduction of morphine-related side effects after major surgery: a systematic review.
    McDaid C; Maund E; Rice S; Wright K; Jenkins B; Woolacott N
    Health Technol Assess; 2010 Mar; 14(17):1-153, iii-iv. PubMed ID: 20346263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA; Derry S; McQuay HJ
    BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs.
    Thomas D; Ali Z; Zachariah S; Sundararaj KGS; Van Cuyk M; Cooper JC
    Am J Cardiovasc Drugs; 2017 Oct; 17(5):343-346. PubMed ID: 28353025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits.
    Gomez Cerezo J; Lubomirov Hristov R; Carcas Sansuán AJ; Vázquez Rodríguez JJ
    Eur J Clin Pharmacol; 2003 Jun; 59(2):169-75. PubMed ID: 12698301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exacerbation of inflammatory bowel disease by nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors: fact or fiction?
    Guslandi M
    World J Gastroenterol; 2006 Mar; 12(10):1509-10. PubMed ID: 16570341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis.
    Wheat CL; Ko CW; Clark-Snustad K; Grembowski D; Thornton TA; Devine B
    BMC Gastroenterol; 2017 Apr; 17(1):52. PubMed ID: 28407755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
    Mukherjee D
    Thromb Haemost; 2006 Oct; 96(4):407-12. PubMed ID: 17003915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury.
    Yang M; Wang HT; Zhao M; Meng WB; Ou JQ; He JH; Zou B; Lei PG
    Medicine (Baltimore); 2015 Oct; 94(40):e1592. PubMed ID: 26448006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COXIBs and non-selective NSAIDs in the gastroenterological setting: what should patients and physicians do?
    Lazzaroni M; Battocchia A; Bianchi Porro G
    Dig Liver Dis; 2007 Jun; 39(6):589-96. PubMed ID: 17459794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
    Moore RA; Derry S; Phillips CJ; McQuay HJ
    BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
    Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastrointestinal safety of coxibs: systematic review and meta-analysis of observational studies on selective inhibitors of cyclo-oxygenase 2.
    Martín Arias LH; Martín González A; Sanz Fadrique R; Salgueiro Vázquez E
    Fundam Clin Pharmacol; 2019 Apr; 33(2):134-147. PubMed ID: 30383903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis.
    Lee C; Hunsche E; Balshaw R; Kong SX; Schnitzer TJ
    Arthritis Rheum; 2005 Aug; 53(4):510-8. PubMed ID: 16082648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials.
    Bjordal JM; Ljunggren AE; Klovning A; Slørdal L
    BMJ; 2004 Dec; 329(7478):1317. PubMed ID: 15561731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of the selection of coxibs over nonselective NSAIDs in an older Medicaid cohort.
    Shireman TI; Rigler SK
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):210-8. PubMed ID: 17062321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP; Deray G; Héloire F
    Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
    Tannenbaum H; Bombardier C; Davis P; Russell AS;
    J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.